"Acenocoumarol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233)
| Descriptor ID |
D000074
|
| MeSH Number(s) |
D03.383.663.283.446.520.079 D03.633.100.150.446.520.079
|
| Concept/Terms |
Sintrom- Sintrom
- Mini-Sintrom
- Mini Sintrom
- MiniSintrom
|
Below are MeSH descriptors whose meaning is more general than "Acenocoumarol".
Below are MeSH descriptors whose meaning is more specific than "Acenocoumarol".
This graph shows the total number of publications written about "Acenocoumarol" by people in this website by year, and whether "Acenocoumarol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2017 | 5 | 1 | 6 |
| 2018 | 5 | 2 | 7 |
| 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Acenocoumarol" by people in Profiles.
-
[Learning with COVID-19: what about anticoagulation?] An Sist Sanit Navar. 2020 Aug 31; 43(2):251-254.
-
New versus Old Oral Anticoagulants: How Can We Set the Scale Needle? Considerations on a Case Report. Medicina (Kaunas). 2019 Mar 17; 55(3).
-
Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. Europace. 2018 09 01; 20(9):1435-1441.
-
Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation. Am J Cardiol. 2018 09 01; 122(5):785-792.
-
Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. Eur J Clin Invest. 2018 Jun; 48(6):e12929.
-
Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation. Am Heart J. 2018 06; 200:32-36.
-
Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. Int J Clin Pract. 2018 Mar; 72(3):e13069.
-
Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry. Thromb Haemost. 2018 02; 118(2):279-287.
-
Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study. Kardiol Pol. 2018; 76(5):889-898.
-
Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. Clin Ther. 2018 01; 40(1):114-122.